A phase I–III umbrella study (NCT05170204) evaluated the efficacy and safety of an ALK-TKI, ROS1-TKI, and rearranged during transfection–TKI in patients with unresectable stage III NSCLC according to their biomarker status [67]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.